Compare · ITOC vs SLNO
ITOC vs SLNO
Side-by-side comparison of iTonic Holdings Ltd (ITOC) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ITOC and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 476.6x ITOC ($5.8M).
- Over the past year, ITOC is down 99.9% and SLNO is down 32.2% - SLNO leads by 67.7 points.
- SLNO has hit the wire 2 times in the past 4 weeks while ITOC has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for ITOC).
- Company
- iTonic Holdings Ltd
- Soleno Therapeutics Inc.
- Price
- $0.36-11.58%
- $53.02+0.08%
- Market cap
- $5.8M
- $2.76B
- 1M return
- +13.69%
- +0.76%
- 1Y return
- -99.87%
- -32.20%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2014
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest ITOC
- SEC Form 6-K filed by iTonic Holdings Ltd
- SEC Form 6-K filed by iTonic Holdings Ltd
- iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- SEC Form 3 filed by new insider Zhang Jianfei
- Amendment: SEC Form 20-F/A filed by iTonic Holdings Ltd
- SEC Form 20-F filed by iTonic Holdings Ltd
- SEC Form 6-K filed by iTonic Holdings Ltd
- SEC Form 3 filed by new insider Zhang Pengfei
- SEC Form 3 filed by new insider Li Zhixin
- SEC Form EFFECT filed by iTonic Holdings Ltd
Latest SLNO
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Norrett Kevin returned 17,786 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Manning Meredith returned 64,507 shares to the company, closing all direct ownership in the company (SEC Form 4)